Literature DB >> 904548

[Secondary failures in modern therapy of diabetes mellitus with blood glucose lowering sulfonamides (author's transl)].

E Haupt, F Laube, H Loy, K Schöffling.   

Abstract

The analysis of the case histories of 914 diabetics exclusively treated with blood glucose lowering sulfonamides in a university clinic outpatient station yielded an annual secondary failure rate of 5-10 p.c. Cumulative incidence calculations showed a continuous increase of secondary failure depending on the duration of treatment. Thus less than 20 p.c. of the diabetics have a chance of a satisfactory long-term therapy after 10 years of treatment. Any dependency of secondary failure from age at onset of diabetes could not be proved. Both "old" and "new" sulfonamide derivatives were equally subject to secondary failure. Changing the treatment from a therapy using grammscale derivatives to any of the modern milligramm-scale substances has been more or less equally "successfull" but lastly unsatisfactory. Diabetics with secondary failure show more overweight than patients with positive long-term treatment

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 904548

Source DB:  PubMed          Journal:  Med Klin        ISSN: 0025-8458


  3 in total

1.  Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents.

Authors:  S Stenman; P H Groop; C Saloranta; K J Tötterman; F Fyhrqvist; L Groop
Journal:  Diabetologia       Date:  1988-04       Impact factor: 10.122

2.  Relationship between hypoglycaemic response and plasma concentrations of BTS 67 582 in healthy volunteers.

Authors:  W D Byrom; N E Rotherham; J R Bratty
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

3.  Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  L Groop; E Widén; A Franssila-Kallunki; A Ekstrand; C Saloranta; C Schalin; J Eriksson
Journal:  Diabetologia       Date:  1989-08       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.